Group	Treatment	PCNA-labeling	Apoptotic		Score	es for:	
no.		index (%)	index (%)	β-Catenin	COX-2	INOS	Nitrotyrosino
1	AOM/DSS	62.4 ± 13.7° (30)	4.1 ± 1.9 (30)	3.7 ± 0.7 (30)	3.3 ± 0.7 (30)	3.0 ± 1.0 (30)	3.1 ± 0.8 (30)
2	AOM/DSS/ 0.04% Nimesulide	38.3 ± 11.1 ^b (6)	11.8 ± 2.9 b (6)	2.3 ± 1.0 ° (6)	1.3 ± 0.5 b (6)	1.3 ± 0.5 b (6)	1.7 ± 0.5 b (6
3	AOM/DSS/ 0.05% Troglitazone	43.6 ± 9.0 ^b (9)	10.0 ± 2.4 b (9)	2.7 ± 0.7 ° (9)	1.8 ± 0.8 ^b (9)	1.6 ± 0.5 b (9)	1.8 ± 0.6 ° (9
4	AOM/DSS/ 0.05% Bezafibrate	40.5 ± 12.7 b (15)	9.7 ± 2.7 b (15)	3.0 ± 0.8 (15)	1.8 ± 0.8 ^b (15)	1.6 ± 0.6 b (15)	2.2 ± 1.1 b (15

text	text	text	text	text			
text		text	text	text	text	text	text
text							
text							
text							
text							

	Without CVRF				With CVRF			
Year	% (n)	ORa (95%)	p-value	change *(%)	% (n)	ORa (95%)	p-value	change *(%)
2006	70.8% (1,913)	1			66.1% (3,289)	1		
2010	78.8% (226)	1.49 (1,12-2.00)	0.009	11.3	75.6% (357)	1.56 (1.25-1.94)	< 0.001	14.4
2011	76.8% (506)	1.35 (1.10-1.65)	0.004	8.5	70.0% (673)	1.19 (1.02-1.39)	0.026	5.9
2012	77.6% (512)	1.40 (1.14-1.72)	0.001	9.6	66.6% (649)	1.01 (0.87-1.17)	0.16	0.8
2013	76.5% (512)	1.32 (1.08-1.61)	0.007	8.1	65.1% (616)	0.94 (0.81-1.09)	0.42	-1.5
2014	69.9% (476)	0.94 (0.78-1.13)	0.511	-1.3	62.3% (548)	0.83 (0.72-0.97)	0.019	-5.7
2015	77.3% (608)	1.18 (0.90)	0.224	9.2	70.6% (745)	1.05 (0.84-1.30)	0.682	6.8

	text				text			
text								
text	text	text			text	text		
text								
text								
text								
text								
text								
text								

Variable	Male		Female		
	%	95% CI	%	95% CI	
Sensitivity	39.13	31.55 to 47.12	37.50	30.49 to 44.92	
Specificity	93.92	92.68 to 95.00	92.42	91.18 to 93.54	
Positive Likelihood Ratio	6.43	4.92 to 8.41	4.95	3.89 to 6.29	
Negative Likelihood Ratio	0.65	0.57 to 0.73	0.68	0.60 to 0.76	
Disease prevalence	8.61	7.37 to 9.97	8.36	7.23 to 9.59	
Positive Predictive Value	37.72	30.35 to 45.54	31.08	25.04 to 37.63	
Negative Predictive Value	94.25	93.04 to 95.31	94.19	93.07 to 95.18	

	text		text	
text	text	text	text	text
text	text	text	text	text
text	text	text	text	text
text	text	text	text	text
text	text	text	text	text
text	text	text	text	text
text	text	text	text	text
text	text	text	text	text

poverty metric	model	r²	RMSE
whole country			
DHS WI	CDR-RS	0.76	0.394
	CDR	0.64	0.483
	RS	0.74	0.413
PPI	CDR-RS	0.25	57.907
	CDR	0.23	58.562
	RS	0.32	57.439
income	CDR-RS	0.27	105.465
	CDR	0.24	107.155
	RS	0.22	108.682
urban			
DHS WI	CDR-RS	0.78	0.424
	CDR	0.70	0.552
	RS	0.71	0.433
PPI	CDR-RS	0.00	60.128
	CDR	0.03	60.935
	RS	0.00	60.384
income	CDR-RS	0.15	168.452
	CDR	0.15	172.738
	RS	0.05	176.705
rural			
DHS WI	CDR-RS	0.66	0.402
	CDR	0.50	0.483
	RS	0.62	0.427
PPI	CDR-RS	0.18	57.397
	CDR	0.17	57.991
	RS	0.21	57.162
income	CDR-RS	0.14	81.979
	CDR	0.13	82.773

text	text	text	text
text			
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text

	text	text	text
	text	text	text
text	text	text	text
text			
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text
text			
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text
	text	text	text
	text	text	text
text	text	text	text

Clinical parameters	WWOX intensity		Total	p value	
	Low (Negative/Weak)	High (Moderate/Strong)			
Grade (GOG)					
1	4 (23%)	13 (77%)	17	p = 0.707	
2	9 (33%)	18 (67%)	27		
3	107 (33%)	215 (67%)	322		
Stage (FIGO)					
	7 (23%)	24 (77%)	31	p = 0.007	
	8 (29%)	20 (71%)	28		
	74 (31%)	168 (69%)	242		
V	31(48%)	34 (52%)	65		
Relapse					
No	31(32%)	66 (68%)	97	p = 0.09	
Yes	61(31%)	137(69%)	198	,	
Progressive disease	27(46%)	32 (54%)	59		
ER					
Negative	22 (25%)	66 (75%)	88	p = 0.984	
Positive	59 (25%)	176 (75%)	235		
PR					
Negative	70 (29%)	170 (71%)	240	p = 0.00	
Positive	12 (14%)	71 (86%)	83	F	

text	text		text	text
	text	text		
text				
text	text	text	text	text
text	text	text	text	
text	text	text	text	
text				
text	text	text	text	text
text	text	text	text	
text	text	text	text	
text	text	text	text	
text				
text	text	text	text	text
text	text	text	text	
text	text	text	text	
text				
text	text	text	text	text
text	text	text	text	
text				
text	text	text	text	text
text	text	text	text	

	Offspring	ANOVA	
	cc	ст	
Birthweight (gm)	3425 ± 490 (n = 408)	3535 ± 495 (n = 126)	P = 0.007
Cord IGF-II (ng/dl)	262 ± 80 (n = 125)	266 ± 98 (n = 36)	P = 0.8

	text		text
	text	text	
text	text	text	text
	text	text	
text	text	text	text
	text	text	

Main cellular process	Modulated pathways	Pv	alue	Genes in pathway		
				Expre	ssed	total
		+ PMN	- PMN	+ PMN	- PMN	-
Cell cycle	Role of APC in cell cycle regulation	1,040E-09	8,149E-08	15	12	32
	Chromosome condensation in prometaphase	4,131E-06	8,392E-11	9	12	20
	The metaphase checkpoint	4,423E-06	1,474E-04	12	9	36
	Spindle assembly and chromosome separation	3,170E-04	1,937E-03	9	7	32
	Start of DNA replication in early S phase	1,284E-03	3,115E-02	8	5	31
	Initiation of mitosis	1,544E-03	2,483E-03	7	6	25
	Sister chromatid cohesion	1,530E-02		5		21
	Transition and termination of DNA replication		1,523E-02		5	26
	Role of Nek in cell cycle regulation		2,390E-02		5	29
	Nucleocytoplasmic transport of CDK/Cyclins		4,386E-02		3	14
Immune response	Alternative complement pathway	4,539E-07	2,737E-02	12	5	30
	Fc gamma R-mediated phagocytosis	1,606E-03	9,058E-03	8	6	32
	Antigen presentation by MHC class II	6,046E-03	2,644E-03	4	4	11
	Classic complement pathway	1,517E-05		12		40
	Antiviral actions of Interferons	2,431E-04		9		31
	CCR3 signalling	8,728E-04		12		59
	Lectin Induced complement pathway	1,251E-03		9		38
	Lipoxin inhibitory action on Superoxide production	1,544E-03	2,483E-03	7	6	25
	IFN alpha/beta signalling pathway	6,214E-03		6		24
	IL-10 signalling pathway	2,245E-02		5		23
	Antigen presentation by MHC class I	3,675E-02		5		26
	Transcription regulation of granulocyte development		3,115E-02		5	31
Oxidative stress	ROS production	8,932E-04	4,113E-02	7	4	23
Apoptosis	Inhibition of ROS induced apoptosis	3,675E-02		5		26
G protein signalling	Rac2 regulation pathway	4,957E-03	4,113E-02	6	4	23
	RAC1 in cellular process	1,361E-02		6		28
Cytoskeleton remodelling	Regulation of actin cytoskeleton by Rho GTPases	8,972E-03			5	23
	Alpha-1A adrenergic receptor-dependent inhibition of PI3K	2,887E-02			3	12
Metabolic process	Lipoprotein metabolism I. Chylomicron, VLDL and LDL metabolism	1,630E-02	9,007E-07	3	6	8
	Lipoprotein metabolism II. HDL metabolism	1,630E-02	9,007E-07	3	6	8
	G-alpha(q) regulation of lipid metabolism	2,245E-02		5		23
	Urea cycle	3,675E-02		5		26
	LDL metabolism during development of fatty streak lesion	1,870E-02			2	4

text	text	text		text		
				text		text
		text	text	text	text	
text						
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text		text		text
	text		text		text	text
	text		text		text	text

	l					
	text		text		text	text
text	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text		text		text
	text	text		text		text
	text	text		text		text
	text	text		text		text
	text	text	text	text	text	text
	text	text		text		text
	text	text		text		text
	text	text		text		text
	text		text		text	text
text	text	text	text	text	text	text
text	text	text		text		text
text	text	text	text	text	text	text
	text	text		text		text
text	text	text			text	text
	text	text			text	text
text	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text		text		text
		text		text		text
	text	ισχι		10/11		10/11
text	text text text text text text text text	text text text text text text text	text	text text text text	text text text	tex tex tex tex tex tex tex

Presenting complaints	N (% of total sample n = 259288)	*Pulse	*BP	* T°C	*GCS	*RR	*SpO ₂
			N (% c	of each presen	ting compla	sints)	
Fever	31554 (12.2)	9964 (31.6)	9645 (30.6)	12528 (39.7)	1170 (3.7)	3797 (12.0)	1288 (4.1)
Injury (non-head/face/neck)	29695 (11.4)	2767 (9.3)	3200 (10.8)	2583 (8.7)	441 (1.5)	2267 (7.6)	1437 (4.8)
Abdominal pain	23170 (8.9)	5886 (25.4)	5986 (25.8)	4516 (19.5))	311 (1.3)	1520 (6.6)	732 (3.2)
Chest pain	20130 (7.8)	8630 (42.9)	9076 (45.1)	7008 (34.8)	1371 (6.8)	5157 (25.6)	1409 (7.0)
Injury (Head/face/neck)	13309 (5.0)	1769 (13.3)	2064 (15.5)	1669 (12.5)	394 (3.0)	1418 (10.7)	852 (6.4)
Vomiting	10629 (4.1)	3135 (29.5)	3372 (31.7)	2508 (23.6)	211 (2.0)	1098 (10.3)	606 (5.7)
Headache	9516 (3.7)	3267 (34.3)	3706 (38.9)	2779 (29.2)	286 (3.0)	887 (9.3)	271 (2.8)
Shortness of breath	8548 (3.3)	2711 (31.7)	3087 (36.1)	1936 (22.6)	219 (2.6)	1436 (16.8)	611 (7.2)
Back pain	8239 (3.2)	1557 (18.9)	1597 (19.4)	1392 (16.9)	39 (0.5)	368 (4.5)	169 (2.1)
Diarrhea	5954 (2.3)	1835 (30.8)	1916 (32.2)	1588 (26.7)	108 (1.8)	608 (10.2)	244 (4.1)
Total	160744 (62.0)	41521 (25.8)	43649 (27.8)	38507 (24.0)	4550 (2.8)	18556 (11.5)	7619 (4.7)

text text text text text text text t	ext
--------------------------------------	-----

		text					
text							
text							
text							
text							
text							
text							
text							
text							
text							
text							
text							

	Mo	MOD		Percent Positive Area		Percent Positive Nuclei	
	CaP	ВР	CaP	ВР	CaP	ВР	
AA	0.34 ± 0.09	0.32 ± 0.06	0.37 ± 0.20	0.45 ± 0.22	0.25 ± 0.15	0.28 ± 0.18	
CA	0.25 ± 0.06	0.30 ± 0.08	0.38 ± 0.25	0.35 ± 0.18	0.26 ± 0.12	0.25 ± 0.11	
	P < 0.05	P > 0.05	P > 0.05	P > 0.05	P > 0.05	P > 0.05	

	text		text		text	
	text	text	text	text	text	text
text						
text						
	text	text	text	text	text	text

Variable	Hazard ratio	95 % CI	p value*
Age (median)			0.716
≤69	1.000		
>69	0.839	0.310-2.268	
Gender			0.142
Male	1.000		
Fernale	0.426	0.152-1.190	
Type of surgery			0.010
Low anterior resection	1.000		
Abdominoperineal resection	3.140	0.919-10.725	
Turnor location			0.710
Upper rectum	1.000		
Middle rectum	1.267	0.381-4.213	
Law rectum	1.716	0.419-7.026	
Grade of differentiation			0.936
G1	1.000		
G2	1.933	0.416-3.423	
G3	1.119	0.137-9.137	
Histologic type			0.299
Adenocarcinoma	1.000		
Adenocarcinoma with mucinous features	0.381	0.096-1.514	
Depth of tumor invasion			0.925
T3	1.000		
T43	0.919	0.316-2.673	
T4b	0.745	0.172-3.223	
Turnor size			0.329
≤4 cm	1.000		
>4 cm	0.594	0.214-1.651	

text	text	text	text
text			text
text	text		
text	text	text	
text			text
text	text		
text	text	text	
text			text
text	text		
text	text	text	
text			text
text	text		
text	text	text	
text	text	text	
text			text

text	text		
text	text	text	
text	text	text	
text			text
text	text		
text	text	text	
text			text
text	text		
text	text	text	
text	text	text	
text			text
text	text		
text	text	text	

World area	Year(s)										
	1995	1996	1997	1998	1999	2000	2001	2002	2003	1995-2003	
Western Europe	720 (32.7)	829 (35.2)	801 (36.3)	870 (38.6)	1037 (41.3)	1324 (43.2)	1223 (43.1)	1125 (40.2)	1147 (41.7)	9076 (39.5)	
USA	982 (44.6)	978 (41.5)	853 (38.6)	829 (36.8)	904 (36.0)	1088 (35.5)	992 (35.0)	972 (34.8)	956 (34.8)	8554 (37.2)	
Asia (excluding Japan)	114 (5.2)	128 (5.4)	132 (6.0)	134 (6.0)	138 (5.5)	154 (5.0)	169 (6.0)	193 (6.9)	186 (6.8)	1348 (5.9)	
Canada	113 (5.1)	144 (6.1)	126 (5.7)	126 (5.6)	139 (5.5)	134 (4.4)	123 (4.3)	129 (4.6)	130 (4.7)	1164 (5.1)	
Oceania	120 (5.5)	116 (4.9)	128 (5.8)	123 (5.5)	111 (4.4)	120 (3.9)	128 (4.5)	140 (5.0)	130 (4.7)	1116 (4.9)	
Japan	94 (4.3)	92 (3.9)	103 (4.7)	107 (4.8)	110 (4.4)	173 (5.6)	120 (4.2)	126 (4.5)	101 (3.7)	1026 (4.5)	
Eastern Europe	24 (1.1)	39 (1.7)	29 (1.3)	28 (1.2)	35 (1.4)	30 (1.0)	33 (1.2)	61 (2.2)	46 (1.7)	325 (1.4)	
Latin America and the Caribbean	8 (0.4)	13 (0.6)	16 (0.7)	19 (0.8)	21 (0.8)	29 (0.9)	31 (1.1)	35 (1.3)	34 (1.2)	206 (0.9)	
Africa	25 (1.1)	19 (0.8)	20 (0.9)	16 (0.7)	13 (0.5)	15 (0.5)	17 (0.6)	16 (0.6)	20 (0.7)	161 (0.7)	
Total	2200 (100)	2358 (100)	2208 (100)	2252 (100)	2508 (100)	3067 (100)	2836 (100)	2797 (100)	2750 (100)	22976 (100	

text	text									
	text									
text										
text										
text										
text										
text										
text										
text										
text										

| text |
|------|------|------|------|------|------|------|------|------|------|------|
| text |

	5	Sulodexide				Control			
	Abdominal pain upper	Nausea	Vomiting	Allergy	Abdominal pain upper	Nausea	Vomiting	Allergy	
Andreozzi et al., 2015	6	0	0	4	5	4	5	1	
Cirujeda and Granado, 2006*	D	0	0	1	0	0	0	3	
Errichi et al., 2004	0	0	0	D	0	0	0	0	
Total		11				18			

	text				text				
	text								
text									
text									
text									
text	text			text					

Side effects	Number of patients with toxicity (%)								
	Grade I	Grade 2	Grade 3	Grade 4	All grades				
Hematological									
Anemia	4 (9.5%)	0	0	0	4 (9.6)				
Leucopenia	4 (9.5%)	2 (4.8%)	0	0	6 (14.2%)				
Neutropenia	1 (2.4%)	1 (2.4%)	2 (4.8%)	0	4 (9.6%)				
Thrombocytopenia	2(4.8%)	2 (4.8%)	0	0	4 (9.6%)				
Non-hematological									
Nausea/Vomiting	5 (11.9%)	11 (26.2%)	0	0	16 (38.1%)				
Mucositis	7 (16.7%)	5 (11.9%)	1 (2.4%)	0	13 (31.0%)				
Neurotoxicity	8 (19.0%)	5 (11.9%)	1 (2.4%)	0	14 (33.3%)				
Diarrhoea	8 (19.0%)	7 (16.6%)	2 (4.8%)	0	17 (40.4%)				
Asthenia	15 (35.7%)	11 (26.2%)	3 (7.1%)	0	29 (69.0%)				
Hyperbilirubinemia	1 (2.4%)	3 (7.1%)	0	0	4 (9.5%)				
Anorexia	5 (11.9%)	3 (7.1%)	0	0	8 (19.0%)				

text	text				
	text	text	text	text	text
text					
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text					
text	text	text	text	text	text

text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text

Distance	Percent Fuel Saving							
(mi)	Improved Speed	Decreased Accel	Eliminat Stops					
1.3	5.9%	9.5%	29.2%					
11.2	2.4%	0.1%	9.5%					
58.7	8.5%	1.3%	8.5%					
57.8	21.7%	0.3%	2.7%					
173.9	58.1%	1.6%	2.1%					

ı)

			text			
text						
text						
text						
text						
text						
text						

		Response (percent) to effects dimension							
		Never V	isited De	entist n = 79	Last visit >1 year ago n = 185	Last visit within I year n = 92			
Domain	Attribute (effect on)	Very bad/Bad	None	Very good/Good	Very good/Good	Very good/Good			
Physical	Eating	6.2	15.0	78.8	73.7	60.9 b			
-	Appearance	3.8	15.0	81.2	71.0	69.6 °			
	Speech	2.5	17.5	80.0	68.3	65.2 b			
	General Health	3.8	20.0	76.2	75.8	67.4			
	Breath	7.5	23.8	68.7	66.1	53.3			
	Comfort/Relaxation	2.5	35.0	62.5	62.4	51.1 °			
Psychological	Sleep	5.0	27.5	67.5	53.2	56.5			
	Confidence	10.0	15.0	75.0	55.4	69.6			
	Worry	5.0	33.8	61.2	53.2	46.7 b			
	Mood	8.8	33.7	57.5	48.4	42.4 b			
	Personality	7.5	23.8	68.7	61.3	57.6			
Social	Social life	7.5	25.0	67.5	67.2	62.0			
	Romantic Relationship	7.5	33.8	58.7	64.0	58.7			
	Smiling	7.5	21.2	71.2	69.4	70.7			
	Work	5.0	38.8	56.2	46.2	43.5 °			
	Finance	0.0	53.8	46.2	34.4	32.6 b			

		text				
		text			text	text
text						
text						
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
text						
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
text						
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text
	text	text	text	text	text	text

	Agency leve	el .		Individual level		
	6-Month (n = 80)	12-Month (n = 80)	18-Month (n = 78)	6-Month (n = 228)	12-Month (n = 222)	18-Month (n = 211)
Number of couples per facilitator: Mean (SD)						
Manual-based	1.38 (4.79)	1.75* (2.53)	1.11 (3.34)	0.46 (2.00)	(240** (1.11)	0.40 (1.49)
Web-based	0.53 (1.47)	0.25* (0.67)	0.98 (2.90)	0.19 (0.91)	0.09** (0.38)	0.37 (1.36)
Overall	0.95 (3.55)	0.70 (1.89)	1.04 (3.10)	0.33 (1.58)	0.25 (0.85)	0.38 (1.42)
Mean of sessions per facilitator: Mean (SD)						
Manual-based	0.49 (1.27)	0.69* (1.31)	0.48 (1.21)	0.41 (1.24)	(2.60* (1.52)	0.50 (1.51)
Web-based	0.23 (0.61)	0.15* (0.39)	0.37 (0.80)	0.24 (0.99)	0.19* (0.83)	0.44 (1.36)
Overall	0.36 (1.00)	0.42 (1.00)	0.42 (1.01)	0.33 (1.13)	0.40 (1.25)	0.47 (1.43)
Implemented at least one session: n (%)						
Manual-based	12 (30%)	14* (35%)	10 (26%)	17 (14%)	22** (19%)	13 (12%)
Web-based	8 (20%)	6* (15%)	9 (23%)	9 (896)	7** (7%)	12 (11%)
Overall	20 (25%)	20 (25%)	19 (24%)	26 (11%)	29 (13%)	25 (12%)
Completed at least one cycle: n (%)						
Manual-based	2 (5%)	4 (10%)	6 (16%)	3 (3%)	6 (5%)	9 (8%)
Web-based	3 (8%)	1 (3%)	6 (15%)	3 (3%)	1 (1%)	8 (8%)
Overall	5 (696)	5 (6%)	12 (15%)	6 (3%)	7 (3%)	17 (8%)

text	text			text		
text						
text						
text						
text						
text						
text						
text						
text						
text						
text						
text						
text						
text						
text						
text						
text						
text						

	Observed Unordered Genotypes/Number of A Alleles in Pool j True Unordered Genotype AABB						
α	BBBB/ 0	ABBB/ I	AABB/ 2	AAAB/ 3	AAAA/ 4		
1	0.063	0.250	0.375	0.250	0.063		
5	0.0002	0.131	0.737	0.131	0.0002		
25	0.000	0.006	0.988	0.006	0.000		
125	0.000	0.000	1.000	0.000	0.000		

	text				
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text
text	text	text	text	text	text

			MALE			
Thyroid condition	Exposed group w	vith dose detected (GI)	Exposed grou	p with doses = 0 (G2)	Not Exp	osed (G3)
	N	%	N	%	N	%
ncidentalomas	15	11,3	8	10,4	17	9,3
Nodules (single or multiple)	5	3,8	7	9,1	34	18,7
Thyroiditis	6	4,5	3	3,9	6	3,3
Healthy	107	80,5	59	76,6	125	68,7
Total	133	100,0	77	100,0	182	100,0
			FEMALE			
Thyroid condition	Exposed group w	with dose detected (GI)	Exposed grou	p with doses = 0 (G2)	Not Exp	osed (G3)
	N	%	N	%	N	%
ncidentalomas	3	9,7%	7	16,7%	26	13,2
Nodules (single or multiple)	1	3,2%	4	9,5%	40	20,3
hyroiditis	2	6,5%	3	7,1%	17	8,6
Healthy	25	80,6%	28	66,7%	114	57,9
otal	31	100,0%	42	100,0%	197	100,0

	text					
text	text		text		text	
	text	text	text	text	text	text
text						
text						
text						
text						
text						
	text					
text	text		text		text	

	text	text	text	text	text	text
text						
text						
text						
text						
text						

Regions	Discharges of	of foreigners	Percentage of total hospitalisation
_	N	%	_
North	178119	62.7	3.1
Piemonte	24978	8.8	3.0
Valle d'Aosta	640	0.2	2.8
Lombardia	70049	24.7	3.3
Bolzano	4842	1.7	4.6
Trento	3386	1.2	3.2
Veneto	30048	10.6	3.1
Friuli Venezia Giulia	5780	2.0	2.5
Liguria	11486	4.0	2.8
Emilia Romagna	26910	9.5	2.8
Center	72837	25.6	3.0
Toscana	24866	8.8	3.4
Umbria	6151	2.2	3.0
Marche	5685	2.0	1.8
Lazio	36135	12.7	3.1
South and Islands	33029	11.6	0.7
Abruzzo	3067	1.1	0.9
Molise	264	0.1	0.4
Campania	11093	3.9	0.9
Puglia	5349	1.9	0.5
Basilicata			
Calabria	2534	0.9	0.6
Sicilia	7586	2.7	0.7
Sardegna	3136	1.1	0.9
Total	283985	100.0	2.2

text	text		text
	text	text	
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text

text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text			
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text

	Exercise plan							
	Date: 2013/08/17 Time: 2:30 pm Frequency: 3-4 times/ week							
	Goal: Exercise regularly							
		Cardiopulmonary traini	ng					
No	Goal of exercise	Type of exercise	Intensity of exercise					
1	Cardiopulmonary function improvement	Swimming	Moderate					
2	Cardiopulmonary function improvement	Brisk walking	Moderate					
2	Cardiopulmonary function improvement	Bicycle	Moderate					
	Resistance training							
No	Goal of exercise	Type of exercise	Intensity of exercise					
1	Upper limb improvement	Core muscle training	High (15-20 times)					
2	Upper limb improvement	Low bridge	High (15-20 times)					
3	Upper limb improvement	Hand training	Moderate (12-15 times)					
4	Upper limb improvement	Hyperextension	High (15-20 times)					
5	Upper limb improvement	Low back training	Moderate (12-15 times)					
6	Lower limb improvement	Wall squat	High (15-20 times)					
7	Lower limb improvement	Squat	High (15-20 times)					
8	Lower limb improvement	Low limb training	High (15-20 times)					
		Stretch training						
No	Goal of exercise	Type of exercise	Intensity of exercise					
1	Flexibility improvement	Pilatisi	High (3-4 rounds, repeat fifteen minutes per round)					
2	Flexibility improvement	Yoga	High (3-4 rounds, repeat fifteen minutes per round)					

text			
text			
text			
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text			
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text
text	text	text	text

text	text	text	text
text	text	text	text
text	text	text	text
text			
text	text	text	text
text	text	text	text
text	text	text	text